2017-1

Nitrate-Rich Beetroot Juice Selectively Lowers Ambulatory Pressures and LDL Cholesterol in Uncontrolled but not Controlled Hypertension: a Pilot Study.

Conor Kerley
Technological University Dublin, conor.kerley@gmail.com

Eamon Dolan

Liam Cormican

Follow this and additional works at: <https://arrow.tudublin.ie/scschbioart>

Part of the [Medical Immunology Commons](#)

Recommended Citation

Kerley, C., Dolan, E., Cormican, L. (2017) Nitrate-rich beetroot juice selectively lowers ambulatory pressures and LDL cholesterol in uncontrolled but not controlled hypertension: a pilot study. *Irish journal of medical science*, 2017 Nov;186(4):895-902. doi: 10.1007/s11845-016-1551-2.

This Article is brought to you for free and open access by the School of Biological Sciences at ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie, gerard.connolly@tudublin.ie.

Irish Journal of Medical Science (1971 -)

Nitrate-rich beetroot juice selectively lowers ambulatory pressures and LDL cholesterol in uncontrolled but not controlled hypertension: a pilot study.

--Manuscript Draft--

Manuscript Number:	IJMS-D-16-00495R1	
Full Title:	Nitrate-rich beetroot juice selectively lowers ambulatory pressures and LDL cholesterol in uncontrolled but not controlled hypertension: a pilot study.	
Article Type:	Original Article	
Keywords:	dietary nitrate, nitrite, nitric oxide, hypertension, blood pressure.	
Corresponding Author:	Conor Kerley, PhD Connolly Hospital Blanchardstown Dublin, IRELAND	
Corresponding Author Secondary Information:		
Corresponding Author's Institution:	Connolly Hospital Blanchardstown	
Corresponding Author's Secondary Institution:		
First Author:	Conor Kerley, PhD	
First Author Secondary Information:		
Order of Authors:	Conor Kerley, PhD	
	Eamon Dolan, MS	
	Liam Cormcian, MD	
Order of Authors Secondary Information:		
Funding Information:	Irish Heart Foundation (IE)	Dr. Conor Kerley
Abstract:	<p>Background Dietary nitrate has been shown to increase nitrate/nitrite levels in multiple populations, with potential blood pressure lowering effects. However, there are few reports among hypertensives.</p> <p>Aims We aimed to assess the effect of daily nitrate in subject with controlled hypertension vs. uncontrolled hypertension.</p> <p>Methods On day 0, hypertensives wore an ambulatory BP monitor (ABPM) for 24h and fasting blood was taken. Subjects then consumed concentrated beetroot juice (12.9mmol nitrate) for 14 consecutive days. On day 14 subjects consumed their last nitrate dose after fasting blood was drawn and again had an ABPM for 24h.</p> <p>Results According to baseline ABPM, 11 subjects had controlled BP while 8 had uncontrolled BP. There were similar, significant increases in serum nitrate/nitrite in both groups. We observed little change in BP variables among controlled hypertensives. However, there were reductions in BP variables in uncontrolled hypertensives where decreases in nighttime DBP ($-6 \pm 4.8\text{mmHg}$), arterial stiffness (-0.08 ± 0.03 ambulatory arterial stiffness index) and LDL ($-0.36 \pm 0.42\text{mmol/L}$) reached significance ($p=0.003$, 0.05 and 0.046 respectively).</p> <p>Conclusions Our results support the existing data suggesting an anti-hypertensive effect of nitrate-containing beetroot juice, but only among those with uncontrolled hypertension.</p>	

Abstract

Background

Dietary nitrate has been shown to increase nitrate/nitrite levels in multiple populations, with potential blood pressure lowering effects. However, there are few reports among hypertensives.

Aims

We aimed to assess the effect of daily nitrate in subject with controlled hypertension vs. uncontrolled hypertension.

Methods

On day 0, hypertensives wore an ambulatory BP monitor (ABPM) for 24h and fasting blood was taken. Subjects then consumed concentrated beetroot juice (12.9mmol nitrate) for 14 consecutive days. On day 14 subjects consumed their last nitrate dose after fasting blood was drawn and again had an ABPM for 24h.

Results

According to baseline ABPM, 11 subjects had controlled BP while 8 had uncontrolled BP. There were similar, significant increases in serum nitrate/nitrite in both groups. We observed little change in BP variables among controlled hypertensives. However, there were reductions in BP variables in uncontrolled hypertensives where decreases in nighttime DBP ($-6 \pm 4.8\text{mmHg}$), arterial stiffness (-0.08 ± 0.03 ambulatory arterial stiffness index) and LDL ($-0.36 \pm 0.42\text{mmol/L}$) reached significance ($p=0.003$, 0.05 and 0.046 respectively).

Conclusions

Our results support the existing data suggesting an anti-hypertensive effect of nitrate-containing beetroot juice, but only among those with uncontrolled hypertension.

Title Page

Title: Nitrate-rich beetroot juice selectively lowers ambulatory pressures and LDL cholesterol in uncontrolled but not controlled hypertension: a pilot study.

Brief title: Beetroot juice lowers blood pressures and LDL.

Abstract word count: 183

Word Count: 2,830

Tables: 3

Figures: 0

Author list

Conor P. Kerley, PhD, BSc, conorkerley@gmail.com,

Eamon Dolan, MD, eamon028@indigo.ie ^c

Liam Cormican, MD, liamcormican@rcsi.ie ^a

^a Respiratory and Sleep Diagnostics Department, Connolly Hospital, Blanchardstown, Dublin 15, Ireland

^b School of Medicine and Medical Sciences, University College Dublin, Belfield, Dublin 4, Ireland.

^c Acute Stroke Unit, Department of Medicine for the Elderly, Connolly Hospital Blanchardstown, Dublin, Ireland.

26 *** Corresponding author:**

27 Conor P. Kerley, PhD, BSc

28 conorkerley@gmail.com

29 +00353831458796

30

31 **Acknowledgements:**

32 This work was funded by the Irish Heart Foundation. The authors also wish to
33 acknowledge Dr. Jamie Blackwell (BSc) of the University of Exeter, who analyzed
34 serum samples for nitrate and nitrite.

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **Abbreviations:**

52 AASI = ambulatory arterial stiffness index;

53 ABPM = ambulatory blood pressure;

54 BMI = body mass index;

55 BP = blood pressure;

56 BRJ = beetroot juice;

57 FMD = flow mediated dilation;

58 HTN = hypertension;

59 NO = nitric oxide;

60 NOS = nitric oxide synthase.

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76 **Abstract**

77 **Background**

78 Dietary nitrate has been shown to increase nitrate/nitrite levels in multiple
79 populations, with potential blood pressure lowering effects. However, there are few
80 reports among hypertensives.

81

82 **Aims**

83 We aimed to assess the effect of daily nitrate in subject with controlled hypertension
84 vs. uncontrolled hypertension.

85

86 **Methods**

87 On day 0, hypertensives wore an ambulatory BP monitor (ABPM) for 24h and fasting
88 blood was taken. Subjects then consumed concentrated beetroot juice (12.9mmol
89 nitrate) for 14 consecutive days. On day 14 subjects consumed their last nitrate dose
90 after fasting blood was drawn and again had an ABPM for 24h.

91

92 **Results**

93 According to baseline ABPM, 11 subjects had controlled BP while 8 had uncontrolled
94 BP. There were similar, significant increases in serum nitrate/nitrite in both groups.
95 We observed little change in BP variables among controlled hypertensives. However,
96 there were reductions in BP variables in uncontrolled hypertensives where decreases
97 in nighttime DBP ($-6 \pm 4.8\text{mmHg}$), arterial stiffness (-0.08 ± 0.03 ambulatory arterial
98 stiffness index) and LDL ($-0.36 \pm 0.42\text{mmol/L}$) reached significance ($p=0.003$, 0.05 and
99 0.046 respectively).

100

101 Conclusions

102 Our results support the existing data suggesting an anti-hypertensive effect of nitrate-
103 containing beetroot juice, but only among those with uncontrolled hypertension.

104 **Keywords:** dietary nitrate, nitrite, nitric oxide, hypertension, blood pressure.

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126 **Introduction**

127 Nitric oxide (NO) is a pluripotent molecule with diverse systemic effects, including
128 systemic vasodilation [1] and blood pressure (BP) regulation [2]. NO bioavailability
129 is reflected by levels of its metabolites; nitrate and nitrite [3]. Multiple studies have
130 shown that NO metabolites are significantly lower in hypertension (HTN) compared
131 to matched controls [4-7]. Additionally, serum NO levels have been reported to
132 correlate negatively with both systolic and diastolic BP [7] and depend on dietary
133 intake in HTN and ischemic stroke [8]. Therefore, dietary interventions to increase
134 either the bioavailability or bioactivity of NO may have clinical utility in HTN.

135

136 Until recently it was assumed that the only route for NO synthesis *in vivo* was via NO
137 synthase (NOS) acting on its substrate, L-arginine. However, nitrite derived from
138 dietary inorganic-nitrate has been shown to be a substrate for NOS-independent
139 production of NO [9]. This involves both enzymatic and non-enzymatic reduction of
140 nitrate to nitrite and to NO. Indeed, dietary nitrate has been shown to act as a
141 precursor, in a dose-dependent manner, to nitrite and hence NO (10). Dietary nitrate
142 has multiple cardioprotective effects as reviewed previously [11-13] and several
143 authors have suggested that dietary nitrate is the major component responsible for the
144 cardioprotective effect of vegetables [11, 13]. Further, a 2013 meta-analysis
145 concluded that dietary nitrate can reduce systolic BP by 4.4mmHg ($p<0.001$) and
146 diastolic BP by 1.1mmHg ($p=0.06$) among those without hypertension (14). There is a
147 lack of data regarding dietary nitrate supplementation among hypertensives. However,
148 two recent randomized, double-blind, placebo-controlled trials of nitrate
149 supplementation among hypertensives have emerged but 24h ABPM results were
150 conflicting [15,16].

151

152 In this proof of concept study, we wanted to assess the effect of 14d dietary nitrate on
153 ambulatory BP, arterial stiffness, serum nitrate/nitrite, lipids as well as renal and liver
154 indices among treated hypertensives. We further wanted to assess any differences
155 between controlled hypertensives and uncontrolled hypertensives as well as any
156 potential adverse outcomes.

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

Materials and Methods

Study design

During this uncontrolled, pilot study, subjects were tested on two separate occasions, baseline (day 1) and endpoint (day 15) (Fig. 1). On both days, in an identical manner and at the same time of day, fasting blood was drawn, the subject was fitted with an ambulatory blood pressure monitor (ABPM) for 24h and demographics, including body mass index as well as habitual dietary, exercise, smoking, alcohol and medication habits were recorded.

Study participants

We conducted an uncontrolled, pilot study of daily nitrate supplementation in clinically stable, Caucasian hypertensive outpatients, established on diverse antihypertensive regimens. We excluded subjects with kidney disease or diabetes and those on organic nitrates.

This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects/patients were approved the Human Research Ethics Committee of Connolly Hospital, Dublin. Informed consent was obtained from all individual participants included in the study.

Beetroot juice

All subjects were asked to consume 140ml beetroot juice (BRJ) daily for 14 consecutive days. We selected this dose (12.9mmol nitrate) as the nitrate content is attainable with a diet rich in vegetables [17]. During the trial all subjects were provided with written and verbal instructions not to alter dietary, tobacco, alcohol,

exercise or medication habits and not to use mouthwash, which is a known inhibitor of dietary nitrate reduction to nitrate [18]. Subjects took their 14th and final dose of BRJ after their second fasted blood sample, while wearing the ABPM for a second occasion. Compliance with the BRJ was assessed with a daily diary.

205

Outcome measures

Twenty four hour ambulatory blood pressure measurement

24h ABPM was performed on day 1 and day 15 using the non-invasive ABPM Spacelabs 90207 machine (Spacelabs Healthcare Ltd., Issaquah, WA, USA). For each assessment, the ABPM was fitted on the upper left arm by a researcher (CPK) in the morning after 10 minutes of quiet rest.

212

An initial BP reading was taken in the clinic and subjects were asked to return to the clinic wearing the ABPM 24h later. The device was programmed to record BP every 30mins between the hours of 07.00 and 23.00 and every 60mins from 23.00 to 07.00. Participants were advised that they could carry out their usual activities but to avoid strenuous exercise. For each BP measurement, volunteers were asked to hang their arm loosely down the side of their body while keeping still until the end of the measurement. If active, the volunteers were instructed to stop and remain stationary while the measurement was being recorded. Proprietary software was used to download readings and produce 24h, daytime (0700–2300 hours) and nighttime (23:00– 07:00 hours) mean BP readings (90256 ABP Report Management System; Spacelabs Healthcare). We defined uncontrolled HTN as either baseline 24h SBP >130mmHg or 24h DBP >80mmHg as recorded with APBM and controlled BP as <130/80mmHg [19]. Ambulatory arterial stiffness index (AASI) was derived from

individual 24h ABPM whereby, regression slope of diastolic BP on systolic BP was computed. AASI was defined as 1 minus the regression slope, as previously described [21].

Biochemical analysis

On day 1 and 15, two fasting, venous blood samples were drawn into serum tubes (Sarstedt Monovette Serum Z) which have a low nitrate/nitrite content before ABPM set up. One tube was analyzed locally in our clinical laboratory for routine lipid parameters (total cholesterol, LDL, HDL), liver (albumin, calcium, urea) and renal (sodium, potassium, creatinine) parameters.

The second tube was centrifuged at 4,000RPM and 4°C for 10m immediately after phlebotomy. Serum was subsequently extracted into Eppendorf tubes and frozen at –80°C and later analyzed for NO metabolites (nitrate/nitrite), which reflect NO bioavailability [3] as previously described [20].

Statistical methods

For this pilot study we did not perform a power calculation. Paired t-tests were used to compare baseline and post BRJ values for each group while unpaired t-tests were used to compare controlled and uncontrolled HTN. Results were expressed as mean $\pm$ standard deviation. All statistical tests were conducted at the two-sided 0.05 significance level using SAS (version 9.0).

251 **Results**

252 **Study population**

253 Of the 55 subjects we screened, twenty subjects were recruited. There was a single
254 drop out (female, 61y, BMI=33.6kg/m²) due to acute complication of an underlying
255 pulmonary issue (unrelated to study). The baseline characteristics of the 19 subjects
256 who completed this pilot study are displayed in table 1. Both groups were composed
257 mainly of males. There was no difference in baseline BMI but the uncontrolled group
258 were significantly younger (49 vs. 60.9y; p=0.023). There was little difference in anti-
259 hypertensive use among the groups (1.5 agents per subject in controlled vs. 1.1 agents
260 per subject in uncontrolled). Throughout the study, there was no reported change in
261 prescribed medication, or habitual diet/exercise between visits.

262

263

264

265

266

267

268

269

270

271

272

273

274

275

Table 1: Baseline characteristics

	Controlled (n 11)		Uncontrolled (n 8)		P-value
	Mean	SD	Mean	SD	
Age (years)	60.9	9.1	49.3	14.5	0.023
Male gender n (%)	10 (91)		7 (88)		-
BMI (kg/m ²)	30.8	2.4	29.5	6.0	0.3
Weight category*					
Healthy range n (%)	0 (0)		2 (25)		-
Overweight n (%)	3 (27)		3 (38)		-
Obese n (%)	8 (73)		3 (38)		-
Smoking status (n)					
Current smoker	0		2 (25)		-
Ex-smoker	7 (64)		4 (50)		-
LLNS	4 (36)		2 (25)		-
Baseline systolic BP	124	14.0	136	11.0	0.035
Baseline diastolic BP	73	9.0	89	8.0	0.0004
Average No. BP meds	1.5		1.1		-
Aspirin n	2		4		-
Statin n	4		4		-
Co-morbidities					
Cerebrovascular disease n	4		1		-
Coronary artery disease n	2		2		-
Hypercholesterolaemia n	4		2		-

BP, blood pressure; LLNS, life-long non-smoker

Biochemistry

Baseline serum nitrate was 116% higher in the uncontrolled group compared to the controlled group but this was not significant (23.6 vs. 50.9μM; p=0.09). In contrast, baseline serum nitrite was 14% lower in the in the uncontrolled group compared to the controlled group. Again this was not significant (98.2 vs. 86.2nM; p=0.25) (table 2).

Table 2: Biochemical indices before and after nitrate supplementation (BRJ)

	Controlled				Uncontrolled				
	Pre-BRJ	Post-BRJ	Absolute change	* P-value	Pre-BRJ	Post-BRJ	Absolute change	* P-value	# P-value
Nitrate (μM)	23.6	181.6	158	0.0018	50.9	155.3	104.4	0.016	0.38
Nitrite (nM)	98.2	174.3	76.1	0.011	86.2	163.7	77.5	0.007	0.89

BRJ, beetroot juice

* p-values are derived from paired t-tests of the absolute change within each group

p-values derived from unpaired t-tests of the absolute changes between groups.

Fasting serum nitrate increased by 770% and 310% in the controlled and uncontrolled groups respectively. Similarly, serum nitrite increased 177% and 190% in the controlled and uncontrolled groups respectively. However, these differences did not reach statistical significance (table 2). Mean LDL concentrations decreased in 7 of 8 subjects in the uncontrolled group (and this reduction was significant compared to the controlled group (3.35 ± 0.47 to 2.99 ± 0.64 vs 2.14 ± 0.67 to 2.47 ± 0.87 ; $p=0.023$). There were no significant differences in any other lipid, liver or renal parameters within or between groups (data not shown).

Ambulatory blood pressure

Average ABPM wear time was 23.3h at baseline and 22.8 at endpoint, with a mean of 34.5 successful readings taken per subject at both baseline and endpoint. Mean group values for 24h, day and night systolic and diastolic BP as well as ambulatory arterial stiffness index (AASI) are displayed in table 3. Consumption of dietary nitrate was not associated with decreased 24h, day or night BP in the controlled hypertensives. In contrast after nitrate consumption, there were reductions in night BP and arterial stiffness in the uncontrolled hypertensives (table 3).

314 **Table 3: Ambulatory blood pressure monitor results**

1 2 3 4	Controlled				Uncontrolled				# P-value
	Pre-BRJ	Post-BRJ	Absolute change	* P-value	Pre-BRJ	Post-BRJ	Absolute change	* P-value	
24h SBP	123.7 ± 13.7	126.8 ± 16.6	3.1	0.2	135.7	133.1	-2.6	0.29	0.09
24h DBP	72.3 ± 8.7	75 ± 10.7	2.7	0.078	88.8	86.1	-2.7	0.15	0.026
1 Day SBP	126.2 ± 13.7	127.5 ± 17.6	1.3	0.42	136.4	136.1	-0.3	0.48	0.33
1 Day DBP	74.5 ± 9.4	75.7 ± 10	1.2	0.39	89.8	88.9	-1	0.42	0.2
Night SBP	118.2 ± 15.4	121.1 ± 15.8	2.9	0.37	125.8	119	-6.8	0.11	0.07
Night DBP	66.5 ± 9.1	72.1 ± 12.8	5.6	0.08	80.3	74.3	-6	0.03	0.0058
Night SBP max	134.8 ± 20	139.6 ± 19	4.8	0.37	145.3 ± 9.6	135 ± 11.6	-10.3	0.1	0.064
Night DBP max	79.5 ± 20.4	85.4 ± 17	5.9	0.18	94.5 ± 6.3	88.1 ± 13.3	-6.4	0.26	0.083
AASI	0.43 ± 0.2	0.48 ± 0.18	0.05	0.13	0.42 ± 0.13	0.34 ± 0.11	-0.08	0.05	0.1
%SBP Dipping	6.2 ± 9.1	4 ± 11.1	-2.2	0.64	9.2 ± 4	13.7 ± 5.3	4.5	0.13	0.21
%DBP Dipping	11 ± 8.1	5.1 ± 12.8	-5.9	0.21	11.7 ± 6.6	17.5 ± 8	5.8	0.09	0.04

315 AASI, ambulatory arterial stiffness index; BRJ, beetroot juice; DBP, diastolic blood pressure; SBP, systolic blood pressure.

316 * p-values are derived from paired t-tests of the absolute change within each group.

317 # p-values derived from unpaired t-tests of the absolute changes between groups.

318

319

320 Adverse events

321 There were no reported adverse events. The BRJ was well tolerated and as reported

322 previously [16], 8 subjects (38%) reported transient, red/pink urine (beeturia).

323

324

325

326

327

328 **Discussion**

329 In this proof of concept study, we demonstrate that daily, nitrate-rich beetroot juice
330 for 14d led to increased NO bioavailability in both controlled and uncontrolled HTN
331 and reductions night BP, AASI as well as LDL cholesterol in uncontrolled
332 hypertensives only. Further, the intervention was well-tolerated, safe and did not lead
333 to excessive BP lowering in controlled HTN.

334

335 Nitrate-rich beetroot juice was associated with significant increases in both serum
336 nitrate and nitrite in controlled and uncontrolled hypertensives. These increases were
337 less than observed in previous, acute studies utilizing the same dose of nitrate [16,17].

338 In this context it is important to note that we collected fasting blood samples and
339 therefore the BRJ would have been consumed 12-24h prior to blood collection.

340 Considering the peak increase in plasma nitrate and nitrite due to exogenous nitrate
341 occurs 2-3h following ingestion [22] it is understandable that the increases in serum
342 nitrate and nitrite we observed were blunted compared to previous studies. It is
343 noteworthy that all subjects had fasting blood samples taken on both day 1 and 15 and
344 were then fitted with the ABPM before consuming BRJ – therefore ABPM recordings
345 were conducted while nitrate was bioactive.

346

347 Here, we observed decreases in BP profiles in uncontrolled hypertensives only. The
348 effects were most apparent in nighttime DBP ($p=0.03$), DBP dipping ($p=0.09$).

349 Although, other variables did not reach statistical significance, this proof of concept
350 study included a small sample and was not powered to detect statistically significant
351 results. In this context, our observations are clinically significant. Since the discovery
352 that dietary nitrate can increase NO bioavailability, much research has focused on its

anti-hypertensive potential. A 2013 meta-analysis concluded that dietary nitrate can reduce systolic BP by 4.4mmHg ($p<0.001$) and diastolic BP by 1.1mmHg ($p=0.06$) in those without hypertension [14]. Despite much recent interest in the anti-hypertensive effect of dietary nitrate, most of the trials in this meta-analysis were of short duration (2h to 15d) and assessed young, healthy adults. There is a lack of interventional data among hypertensives. A 2013 pilot study, provided evidence that dietary nitrate was a plausible antihypertensive agent. In a small cohort of untreated, stage 1 hypertensives exogenous nitrate increased plasma nitrite 150% and this was associated with decreases in mean 24h in systolic- (-11.2mmHg; $p<0.001$) and diastolic-blood pressure (-9.6mmHg; $p<0.001$) [23]. Two recent, well-conducted trials provided conflicting evidence, one demonstrating benefit [15] and another, no effect [16]. These differences may be due to differing dosing regimens, intervention periods and patient demographics including BMI, age and medications. Our results suggest that any reduction of BP in treated hypertensives may be greatest among those with higher initial BP and after ≥ 7 d of nitrate dosing. This observation is consistent with previous studies [15, 16, 24].

Plasma nitrite reflects flow mediated dilation (FMD) [25] and through its bioactivation to NO is recognized to be a critical pathway regulating basal vascular tone, arterial stiffness and BP [25, 26]. Therefore altering plasma nitrite, including by dietary means, has potential to affect endothelial function and arterial stiffness. In addition to BP reduction, we also observed a significant reduction in arterial stiffness ($p=0.05$). Previous randomized, controlled crossover trials have demonstrated that dietary nitrate can significantly decrease arterial stiffness and significantly improve endothelial function in healthy subjects acutely (2-6 hours) in conjunction with

significantly increased NO metabolites [22-31] These studies utilized nitrate doses
varying from 1.1-22.5mmol. Further, 20 healthy overweight/ slightly obese men were
randomized to a high fat meal with nitrate-rich BRJ (8.1mmol nitrate) or nitrate-
depleted BRJ. Postprandial impairment in FMD was improved after the nitrate-rich
BRJ compared with placebo (-0.37% vs -1.56%; p=0.03) [31]. Further, the effect
appears to be maintained as evidenced by longer trials (7d) [30]. However, 7d of a
high-nitrate diet (4.84mmol nitrate/day from green leafy vegetables) compared to a
low-nitrate diet did not affect multiple BP variables or arterial stiffness among
middle aged adults with high-normal BP (SBP=120-139mmHg) [32]. Nevertheless, a
double-blind, randomized, controlled trial of drug-treated (n=34) and drug-naïve
(n=34) hypertensives demonstrated that 28d of 6.4mmol nitrate improved endothelial
function (FMD) by ~20% (P<0.001) and reduced arterial stiffness (as assessed by
pulse wave velocity) by 0.59 m/s (0.24-0.93; P<0.01) [15].

We also demonstrate for the first time that 14d dietary nitrate significantly decreased
serum LDL among 8 subjects with uncontrolled HTN. According to the Third Report
of The National Cholesterol Education Program [33], baseline LDL levels in the
uncontrolled hypertensives were in the ‘borderline high’ category. After 14d dietary
nitrate, LDL levels were ‘near optimal/above optimal’ category (p=0.046). This
reduction was specific to the uncontrolled HTN group and was significant compared
to controlled hypertensives (p=0.023). This observation is interesting, particularly in
light of our small sample size, short intervention period and considering there was no
change in diet, exercise or medications, including antihyperlipidaemic medications.
We cannot however, rule out a type one error, particularly because we are not aware
of any human intervention study involving provision of dietary nitrate which reported

cholesterol or its subfractions. In this context, it is interesting that decreased basal plasma nitrate/nitrite level has been reported in hypercholesterolemic subjects with suspected coronary artery disease but not in normocholesterolemic subjects [34]. Hypercholesterolemia may reduce the NO bioavailability and several explanations have been offered for this, including decreased availability of L-arginine, the substrate for NOS [35]; decreased synthesis of NO through degeneration of endothelial G-protein or G-protein-dependent pathways [36] and reduced expression of endothelial NOS [37, 38]. Further, plasma nitrate/nitrite levels have previously been reported to correlate negatively with both total cholesterol ($r = -0.40$, $p < 0.01$) and LDL cholesterol levels ($r = -0.37$, $p < 0.003$) [34]. Interestingly statins, widely prescribed for their cholesterol lowering properties activate endothelial NOS [39]. Further, there is evidence that 8 weeks of dietary nitrate (100 mg/L in drinking water) reduced LDL cholesterol in normal (1.12 to 0.75 mmol/L; $p < 0.05$) and diabetic rats (1.12 to 0.46 mmol/L; $p < 0.05$) compared to normal and diabetic rats without nitrate [40]. Although, our study cannot provide mechanistic insight for the LDL reductions, our data provide preliminary evidence for the first time that dietary nitrate reduces LDL levels in uncontrolled hypertensive patients. This observation is consistent with preliminary research suggesting that nitrate targets a novel pathway to enhance fat metabolism and/or energy utilization [41] and decreases lipid levels in animal models [40-42].

NO has multiple roles in cardio-metabolic regulation. Several comprehensive reviews have highlighted the diverse cardioprotective effects of dietary nitrate [11-13]. Some authors have even suggested that dietary nitrate is the major component responsible for the cardioprotective effect of vegetables [11, 12]. It has been demonstrated that

1 dietary nitrate acts as a precursor to NO in a dose-dependent manner where by a single
2 serving of a nitrate-rich vegetables contains more nitrate than what is formed
3
4 endogenously by the all three NOS isoforms combined in 24h [9]. Dietary nitrate
5
6 increases vasodilation as well as inhibiting production of mitochondrial reactive
7
8 oxygen species and platelet aggregation. Despite the complex nature of NO and the
9
10 multiple contributors to NO bioavailability (e.g. underlying pathology, medication
11
12 use, serum lipids, tobacco exposure, exercise, alcohol intake), diet has been shown to
13
14 be the major influencer of serum NO in patients with HTN and ischemic stroke [8].
15
16 In this context, our results and those of others should not be considering surprising.
17
18
19
20
21
22
23
24 This trial has several key strengths. The use of 24h ABPM provides a robust, reliable
25
26 method of determining BP. We asked subjects to maintain their typical dietary,
27
28 exercise, alcohol, tobacco and medication habits throughout this study. Therefore our
29
30 observations closely reflect that effect of supplementary nitrate to the everyday lives
31
32 of hypertensives. The increases in serum nitrate and nitrite confirmed compliance
33
34 with the intervention.
35
36
37
38
39
40
41 This pilot study did not include a control arm or a placebo. Therefore, it is possible
42
43 that any observed effect was simply regression to the mean. It is also possible that any
44
45 effect observed here may be due to non-nitrate components of beetroot juice.
46
47
48 However, emerging trials utilizing nitrate-rich beetroot juice and identical, nitrate-
49
50 depleted beetroot juice have demonstrated no physiological effect of nitrate-depleted
51
52 beetroot juice. Further, our results are consistent with a recent meta-analysis [14] and
53
54 a double-blind, randomized, placebo-controlled trial [15]. Therefore we suggest that
55
56 our observations are due to dietary nitrate. The number of participants in our study (n
57
58
59
60
61
62
63
64
65

453 = 19) may be considered small. However, many previous studies investigating
454 chronic nitrate intake on BP had similar numbers [16, 24].
455
456 In this pilot study, we observed significant decreases in night DBP, AASI and LDL
457 cholesterol in conjunction with increased serum NO metabolites. These effects were
458 confined to subjects with uncontrolled BP, suggesting that the physiological effects of
459 exogenous nitrate may be greatest in these patients. Considering the conflicting data
460 in the area, our pilot results should be confirmed with well-designed trials,
461 particularly regarding LDL.
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477

478 **Ethical approval:**

479 “All procedures performed in studies involving human participants were in
480 accordance with the ethical standards of the institutional and/or national research
481 committee and with the 1964 Helsinki declaration and its later amendments or
482 comparable ethical standards.”

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503 **References**

- 504 1. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. *Handb Exp*
505 *Pharmacol.* 2006;176: 213– 254.
- 506 2. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide
507 in the regulation of blood pressure. *Proc Natl Acad Sci U S A.* 1989;86: 3375-
508 8.
- 509 3. Kleinbongard P, Dejam A, Lauer T, *et al.* Plasma nitrite reflects constitutive
510 nitric oxide synthase activity in mammals. *Free Radic Biol Med.* 2003;35:
511 790-6.
- 512 4. Linder L, Kiowski W, Bühler FR, *et al.* Indirect evidence for release of
513 endothelium-derived relaxing factor in human forearm circulation in vivo.
514 Blunted response in essential hypertension. *Circulation.* 1990;81: 1762-7.
- 515 5. Forte P, Copland M, Smith LM, *et al.* Basal nitric oxide synthesis in essential
516 hypertension. *Lancet.* 1997;349: 837-42.
- 517 6. Shiekh GA, Ayub T, Khan SN, *et al.* Reduced nitrate level in individuals with
518 hypertension and diabetes. *J Cardiovasc Dis Res.* 2011;2: 172-6.
- 519 7. Ghasemi A, Zahediasl S, Syedmoradi L, *et al.* Association between serum
520 nitric oxide metabolites and hypertension in a general population. *Int Angiol.*
521 2011;30: 380-7
- 522 8. Gumanova NG, Teplova NV, Ryabchenko AU, *et al.* Serum nitrate and nitrite
523 levels in patients with hypertension and ischemic stroke depend on diet: a
524 multicenter study. *Clin Biochem.* 2015;48: 29-32.
- 525 9. Lundberg JO, Gladwin MT, Ahluwalia A, *et al.* Nitrate and nitrite in biology,
526 nutrition and therapeutics. *Nat Chem Biol* 2009;5: 865–9.

- 527 10. Bondonno CP, Croft KD, Puddey IB, *et al.* Nitrate causes a dose-dependent
528 augmentation of nitric oxide status in healthy women. Food Funct. 2012,3:
529 522-7.
- 530 11. Lundberg JO, Feelisch M, Björne H, *et al.* Cardioprotective effects of
531 vegetables: is nitrate the answer? Nitric Oxide. 2006,4: 359-62.
- 532 12. Lidder S, Webb AJ. Vascular effects of dietary nitrate (as found in green leafy
533 vegetables and beetroot) via thenitrate-nitrite-nitric oxide pathway. Br J Clin
534 Pharmacol. 2013,75: 677-96.
- 535 13. Rathod KS, Velmurugan S, Ahluwalia A. A 'green' diet-based approach to
536 cardiovascular health? Is inorganic nitrate the answer? Mol Nutr Food Res.
537 2016,60: 185-202.
- 538 14. Siervo M, Lara J, Ogbonmwan I, *et al.* Inorganic nitrate and beetroot juice
539 supplementation reduces blood pressure in adults: a systematic review and
540 meta-analysis. J Nutr 2013,143: 818-26.
- 541 15. Kapil V, Khambata RS, Robertson A, *et al.*
542 Dietary nitrate provides sustained blood pressure lowering in hypertensive pati
543 ents: a randomized, phase 2, double-blind, placebo-controlled study.
544 Hypertension. 2015,65: 320-7.
- 545 16. Bondonno CP, Liu AH, Croft KD, *et al.* Absence of an effect of high nitrate
546 intake from beetroot juice on blood pressure in treated hypertensive
547 individuals: a randomized controlled trial. Am J Clin Nutr. 2015,102: 368-75.
- 548 17. Sobko T, Marcus C, Govoni M, *et al.* Dietary nitrate in Japanese traditional
549 foods lowers diastolic blood pressure in healthy volunteers. Nitric Oxide.
550 2010,22: 136-40.

18. Petersson J, Carlström M, Schreiber O, *et al.* Gastroprotective and blood pressure lowering effects of dietary nitrate are abolished by an antiseptic mouthwash. *Free Radic Biol Med.* 2009,46: 1068-75.
19. Mancia G, Fagard R, Narkiewicz K, *et al.* 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens.* 2013,31: 1281-357.
20. Kerley CP, Cahill K, Bolger K, *et al.* Dietary nitrate supplementation in COPD: an acute, double-blind, randomized, placebo-controlled, crossover trial. *Nitric Oxide.* 2015,44: 105-11.
21. Li Y, Wang JG, Dolan E, Gao PJ, Guo HF, Nawrot T, Stanton AV, Zhu DL, O'Brien E, Staessen JA. Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. *Hypertension.* 2006 Mar;47(3):359-64.
22. Webb AJ, Patel N, Loukogeorgakis S, *et al.* Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. *Hypertension.* 2008,51: 784–790.
23. Ghosh SM, Kapil V, Fuentes-Calvo I, *et al.* Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. *Hypertension.* 2013,61: 1091-102.
24. Jajja A, Sutjarjoko A, Lara J, *et al.* Beetroot supplementation lowers daily systolic blood pressure in older, overweight subjects. *Nutr Res* 2014, 34: 868–75.
25. Casey DP, Beck DT, Braith RW. Systemic plasma levels of nitrite/nitrate (NOx) reflect brachial flow-mediated dilation responses in

- 576 young men and women. Clin Exp Pharmacol Physiol. 2007, 34: 1291-3.
- 577 26. Jin, R.C.; Loscalzo, J. Vascular nitric oxide: Formation and function. J. Blood
578 Med. 2010,1: 147–162.
- 579 27. Bondonno CP, Yang X, Croft KD, *et al.* Flavonoid-rich apples and nitrate-rich
580 spinach augment nitric oxide status and improve endothelial function in
581 healthy men and women: A randomized controlled trial. Free Radic. Biol.
582 Med. 2012,52: 95–102.
- 583 28. Hobbs DA, Goulding MG, Nguyen A, *et al.* Acute ingestion of beetroot bread
584 increases endothelium-independent vasodilation and lowers diastolic blood
585 pressure in healthy men: a randomized controlled trial. J Nutr. 2013, 143:
586 1399-405.
- 587 29. Liu AH, Bondonno CP, Croft KD, *et al.* Effects of a nitrate-rich meal on
588 arterial stiffness and blood pressure in healthy volunteers. Nitric Oxide. 2013,
589 35: 123-30.
- 590 30. Jovanovski E, Bosco L, Khan K, *et al.* Effect of Spinach, a High Dietary
591 Nitrate Source, on Arterial Stiffness and Related Hemodynamic Measures: A
592 Randomized, Controlled Trial in Healthy Adults. Clin Nutr Res. 2015, 4: 160-
593 7.
- 594 31. Joris PJ, Mensink RP. Beetroot juice improves in overweight and slightly
595 obese men postprandial endothelial function after consumption of a mixed
596 meal. Atherosclerosis. 2013, 231: 78-83.
- 597 32. Bondonno CP, Liu AH, Croft KD, *et al.* Short-term effects of nitrate-rich
598 green leafy vegetables on blood pressure and arterial stiffness in individuals
599 with high-normal blood pressure. Free Radic Biol Med. 2014, 77: 353-62.

- 600 33. Expert Panel on Detection, Evaluation,
601 and Treatment of High Blood Cholesterol in Adults. Executive Summary of
602 The Third Report of The National Cholesterol Education Program (NCEP)
603 Expert Panel on Detection, Evaluation,
604 And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel
605 III). JAMA. 2001,285: 2486-97.
- 606 34. Tanaka S, Yashiro A, Nakashima Y, *et al.* Plasma nitrite/nitrate level is
607 inversely correlated with plasma low-density lipoprotein cholesterol level.
608 Clin Cardiol. 1997,20: 361-5.
- 609 35. Drexler H, Zeiher AM, Meinzer K, *et al.* Correction of endothelial dysfunction
610 in coronary microcirculation of hypercholesterolaemic patients by L-arginine.
611 Lancet. 1991, 338: 1546-50.
- 612 36. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction.
613 Potential mechanisms underlying reduction in EDRF/nitric oxide activity.
614 Circulation. 1992, 85: 1927-38.
- 615 37. Liao JK, Shin WS, Lee WY, *et al.* Oxidized low-density lipoprotein decreases
616 the expression of endothelial nitric oxide synthase. J Biol Chem. 1995,270:
617 319-24.
- 618 38. Chen LY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake
619 and nitric oxide synthase protein expression in human platelets: relevance of
620 the effect of oxidized LDL on platelet function. Circulation. 1996, 93: 1740-6.
- 621 39. Kaesemeyer WH, Caldwell RB, Huang J, *et al.* Pravastatin sodium activates
622 endothelial nitric oxide synthase independent of its cholesterol-lowering
623 actions. J Am Coll Cardiol 1999, 33: 234-241.

- 624 40. Khalifi S, Rahimipour A, Jeddi S, *et al.* Dietary nitrate improves glucose
625 tolerance and lipid profile in an animal model of hyperglycemia. Nitric Oxide.
626 2015,44: 24-30.
- 627 41. Stokes KY, Dugas TR, Tang Y, *et al.* Dietary nitrite prevents
628 hypercholesterolemic microvascular inflammation and reverses endothelial
629 dysfunction. Am J Physiol Heart Circ Physiol. 2009, 296: H1281-8.
- 630 42. Carlström M, Larsen FJ, Nyström T, *et al.* Dietary inorganic nitrate reverses
631 features of metabolic syndrome in endothelial nitric oxide synthase-deficient
632 mice. Proc Natl Acad Sci U S A. 2010, 107: 17716-20.

633

Authorship Form

Irish Journal of Medical Science

Manuscript ID Number:

Article Title: (first few words) NITRATE-RICH BEETROOT JUICE SELECTIVELY

First Author: CONOR KERLEY

E-mail: CONORKERLEY@GMAIL.COM

AUTHORSHIPI, the undersigned author(s), certify that:

I have seen and approved the final version of the manuscript, and all subsequent versions;

I have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;

I have drafted the article or revised it critically for important intellectual content.

I accept public responsibility for it, and believe it represents valid work. As an author of this article, I certify that none of the material in the manuscript has been previously published, nor is included in any other manuscript. I certify that this manuscript is not under consideration for publication elsewhere, nor has it been submitted or accepted in another publication in any form. The rights or interest in the manuscript have not been assigned to any third party.

Moreover, should the editor of *Irish Journal of Medical Science* request the data upon which the manuscript is based, I shall produce it. I also certify that I have read and complied with the copyright information, as found on the journal home page website.

After submission of this agreement signed by all authors, changes of authorship or in the order of the authors listed will not be accepted by Springer.

☒ CONORKERLEY

Author's signature

CONORKERLEY 10/10/16

Printed name & date

☒ Liam Cormican

Author's signature

LIAM CORMICAN 10/10/16

Printed name & date

☒ Eamon Dolan

Author's signature

Eamon Dolan 10/10/16

Printed name & date

☐

Author's signature

Printed name & date

☐

Author's signature

Printed name & date

☐

Author's signature

Printed name & date

☐

Author's signature

Printed name & date

☐

Author's signature

Printed name & date

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)
Eamon

2. Surname (Last Name)
Dolan

3. Date
12-October-2016

4. Are you the corresponding author?

☐ Yes ☒ No

Corresponding Author's Name
Conor Kerley

5. Manuscript Title
Nitrate-rich beetroot juice selectively lower ambulatory pressures and LDL cholesterol in uncontrolled but not controlled hypertension.

6. Manuscript Identifying Number (if you know it)

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☒ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☒ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☒ No

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
- ☒ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Dolan has nothing to disclose.

Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)
Liam
2. Surname (Last Name)
Cormican
3. Date
12-October-2016
4. Are you the corresponding author? ☐ Yes ☒ No Corresponding Author's Name
Conor Kerley
5. Manuscript Title
Nitrate-rich beetroot juice selectively lower ambulatory pressures and LDL cholesterol in uncontrolled but not controlled hypertension.
6. Manuscript Identifying Number (if you know it)

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☒ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☒ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☒ No

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
- ☒ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Cormican has nothing to disclose.

Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)
Conor

2. Surname (Last Name)
Kerley

3. Date
12-October-2016

4. Are you the corresponding author? ☒ Yes ☐ No

5. Manuscript Title
Nitrate-rich beetroot juice selectively lower ambulatory pressures and LDL cholesterol in uncontrolled but not controlled hypertension.

6. Manuscript Identifying Number (if you know it)

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☒ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☒ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☒ No

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
- ☒ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Kerley has nothing to disclose.

Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.